ATS GUIDELINES Bundle

Tobacco

American Thoracic Society Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1299829

Contents of this Issue

Navigation

Page 3 of 5

➤ For tobacco-dependent adults in whom treatment is being initiated, we suggest varenicline over electronic cigarettes (conditional recommendation, very low certainty in the estimated effects). Remarks: The recommendation's strength reflects very low certainty in the effects used to derive the recommendation. After our evidence synthesis, new evidence emerged regarding serious adverse effects of electronic cigarettes. If these serious adverse effects continue to be reported, the strength of the recommendation should be reevaluated. Note that this recommendation is intended for treatment of tobacco dependence under the supervision of a clinician; it should not be extrapolated to unsupervised treatment or recreational use. ➤ In tobacco-dependent adults who are not ready to discontinue tobacco use, we recommend that clinicians begin treatment with varenicline rather than waiting until patients are ready to stop tobacco use (strong recommendation, moderate certainty in the estimated effects). ➤ For tobacco-dependent adults with comorbid psychiatric conditions, including substance-use disorder, depression, anxiety, schizophrenia, and/or bipolar disorder, for whom treatment is being initiated, we recommend varenicline over a nicotine patch (strong recommendation, moderate certainty in the estimated effects). ➤ For tobacco-dependent adults for whom treatment is being initiated with a controller, we recommend using extended- duration (>12 wk) over standard-duration (6–12 wk) therapy (strong recommendation, moderate certainty in the estimated effects).

Articles in this issue

view archives of ATS GUIDELINES Bundle - Tobacco